Clinical trials: Lung Cancer (Diagnosis)
Breast Cancer, Lung Cancer
Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.
Novel treatment modalities like targeted therapies and Immune checkpoint inhibitors have revolutionised the therapeutic landscape in oncology and hematology, significantly improving outcomes even in clinical contexts in which…
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Head and Neck Cancer
- Trial name
- POSITive (NCT06321640)
- Testing
- Cohort A: primarily operable disease, candidate to adjuvant, Cohort B: locally advanced disease, Cohort C: metastatic disease
- Where
- Italy
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
Non-Small Cell Lung Cancer, Pulmonary Metastases
Pulsed Field Ablation for the Treatment of Malignant Lung Tumors
This prospective, single-center, single-arm exploratory study will evaluate the safety and effectiveness of a pulsed field ablation system and a single-use pulsed field ablation catheter for the treatment of malignant lung…
- Trial name
- NCT07889297
- Testing
- Pulsed Field Ablation System and Single-Use Pulsed Field Ablation Catheter
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Chest Hospital
Malignant Pleural Mesothelioma, Nonsquamous Nonsmall Cell Neoplasm of Lung
Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin
This is a prospective, open-label, mono-centric, phase I-Ib trial of Tivantinib in combination with Pemetrexed and Carboplatin as first-line therapy in patients with advanced or metastatic cancer suitable for a Carboplatin and…
- Trial name
- NCT02049060
- Testing
- Tivantinib
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- Armando Santoro, MD
Small Cell Lung Carcinoma
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
Maintenance durvalumab (MEDI4736) and olaparib (AZD2281) after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC)
- Trial name
- GUIDANCE (NCT06419179)
- Testing
- Durvalumab, Olaparib
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- University of Cologne
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
- Trial name
- NCT07085091
- Testing
- ALX2004
- Where
- 12 sites in United States
- Volunteers
- 170 people
- Sponsor
- ALX Oncology Inc.
Non-small Cell Lung Cancer
Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma
Determine whether patients have a decreased incidence of grade 3 and grade 4 neutropenia when Filgrastim-SD/01 is given with docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00050674
- Testing
- Filgrastim-SD/01
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Schwartzberg, Lee, M.D.
Lung Cancer (Diagnosis)
Effect of Apneic Oxygenation of the Non-ventilated Lung During Lung Cancer Surgery.
This study investigates the effect of apneic oxygenation of the non-ventilated lung on local and systemic inflammatory response during lung cancer surgery.
- Trial name
- NCT07393490
- Testing
- Apnoeic Oxygenation, Standard Ventilation
- Where
- Croatia
- Volunteers
- 56 people
- Sponsor
- Osijek University Hospital
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
The purpose of this study is to evaluate the objective tumor response rate (based on the RECIST criteria) to SNS-595 as a second-line therapy in patients with advanced NSCLC.
- Trial name
- NCT00252382
- Testing
- SNS-595 Injection
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sunesis Pharmaceuticals
Lung Cancer
The Impact of Lung Cancer-derived Fibroblasts on Mast Cells Activation
In addition to their role in allergic inflammation, mast cells are often found at the site of tumors. They have been attributed both to pro- and anti-tumorigenic roles depending on the tumor type.
- Trial name
- NCT02161523
- Volunteers
- 20 people
- Sponsor
- Meir Medical Center
Carcinoma, Non-Small-Cell Lung
Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages of Non-small Cell Lung Cancer
Randomized Phase III trial of surgery alone or surgery plus preoperative Gemcitabine-Cisplatin in clinical early stages of non-small cell lung cancer
- Trial name
- NCT00540280
- Testing
- Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin
- Volunteers
- 10 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Insomnia
Insomnia Interventions in Cancer Survivors
This study looks at two different interventions used for the treatment of insomnia in survivors of breast, colon, lung, prostate and gynecologic cancer.
- Trial name
- NCT02783079
- Testing
- CBT, MBSR
- Where
- 2 sites in United States
- Volunteers
- 210 people
- Sponsor
- Cooper Norcross Health
Lung Cancer, Non Small Cell Lung Cancer
The Development, Safety, and Feasibility of an Artificial Intelligence-Powered Platform (NodeAI) for Real-Time Prediction of Mediastinal Lymph Node Malignancy During Endobronchial Ultrasound Staging for Lung Cancer
Lung cancer is the leading cause of annual cancer deaths globally, more than breast, prostate, and colon cancers combined. The staging of chest lymph nodes (LNs) is a crucial step in the lung cancer diagnostic pathway because it…
- Trial name
- NodeAI (NCT06540196)
- Testing
- NodeAI, Surgeon
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- McMaster University
Local Advanced or Metastatic NSCLC
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
This study is aimed to evaluate the efficacy and safety of the Garsorasib combination therapy in KRAS G12C mutant locally advanced and metastatic NSCLC
- Trial name
- NCT07294261
- Testing
- Garsorasib, Benmelstobart, Anlotinib, Benmelstobart, Anlotinib, Garsorasib, Cetuximab Beta Injection
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Sun Yat-sen University
Carcinoma Neuroendocrine, Small Cell Lung Carcinoma
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
BACKGROUND: The histone deacetylase (HDAC) inhibitors are a novel class of anticancer agent. These agents lead to the increased acetylation of both histone and non-histone proteins, which leads to rapid cell death in many tumor…
- Conditions
- Carcinoma Neuroendocrine, Small Cell Lung Carcinoma, Malignant Epithelial Neoplasms
- Trial name
- NCT00926640
- Testing
- Belinostat, Cisplatin, Etoposide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC (Non-small Cell Lung Carcinoma)
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is…
- Trial name
- NCT02119650
- Testing
- Ruxolitinib, Pemetrexed, Cisplatin
- Where
- 30 sites in United States
- Volunteers
- 76 people
- Sponsor
- Incyte Corporation
Lung Cancer
Early Detection of Lung Cancer in a High-Risk Population Defined by PFT, Biomarkers, and CT Scanning
Lung cancer is the number one cancer killer in Kentucky and has a very high incidence within the 5th Congressional District of Kentucky (110.8 cases per 100,000 in period 1996-2000).
- Trial name
- NCT00596310
- Testing
- CT
- Where
- 4 sites in United States
- Volunteers
- 531 people, healthy volunteers welcome
- Sponsor
- Susanne Arnold
Lung Carcinoma, Lower Oesophageal Carcinoma
Evaluation of 4D-contrast Enhanced PET-CT in Tumour Volume Definition
The aim of high dose radiotherapy treatment is to deliver enough radiation to the tumour to kill all the cancer cells while at the same time giving a low dose of radiation to the normal parts of the body to reduce the side…
- Conditions
- Lung Carcinoma, Lower Oesophageal Carcinoma, Pancreatic Carcinoma
- Trial name
- NCT02285660
- Testing
- 4D PET-CT Scan, No intervention
- Where
- United Kingdom
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
This randomized phase II trial is to see if combination chemotherapy works better with or without bevacizumab in treating patients who have malignant mesothelioma.
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma
- Trial name
- NCT00027703
- Testing
- gemcitabine hydrochloride, cisplatin, bevacizumab
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Neoplasm, ALK Fusion Protein Expression
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
This phase II trial studies how well brigatinib works in treating patients with ALK and ROS1 gene alterations and solid cancers that have spread to nearby tissue and lymph nodes or other places in the body.
- Conditions
- Advanced Malignant Neoplasm, ALK Fusion Protein Expression, ALK Gene Amplification, ALK Gene Mutation
- Trial name
- NCT03868423
- Testing
- Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- United States
- Sponsor
- Sameek Roychowdhury
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.